logo
  

EMC Corp Q3 Profit Rises; Cuts 2014 Outlook - Quick Facts

EMC Corp. (EMC) reported that its third-quarter net income attributable to the company increased to $587 million from the prior year's $586 million, with earnings per share improving to $0.28 from $0.27 last year.

Non-GAAP net income attributable to the company was $903 million or $0.438 per share, compared to $860 million or $0.397 per share in the prior year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.46 per share for the quarter. Analysts' estimates typically exclude special items.

Quarterly revenue grew to $6.032 billion from $5.539 billion in the prior year. Wall Street expected revenues of $6.00 billion.

Looking ahead for fiscal 2014, the company now expects GAAP earnings per share to be $1.29 for 2014 and non-GAAP earnings share of $1.90, and Consolidated revenues of $24.5 billion. Wall Street currently is looking for fiscal year 2014 earnings of $1.91 per share on annual revenues of $24.54 billion.

The company said in July that it expected GAAP earnings per share to be $1.30 and non-GAAP earnings per share of $1.91 and Consolidated revenues of $24.575 billion for 2014.

EMC expects to repurchase an aggregate of $3.0 billion of the company's common stock in 2014.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT